CapsoVision appoints David S. Shields to board

CapsoVision, Inc announced the appointment of David S. Shields, M.D., to its Board of Directors.

Dr Shields is a board-certified gastroenterologist with more than 40 years of experience in academic medicine, clinical gastroenterology, advanced endoscopy and digestive disease management. He has served as a clinical advisor and consultant to CapsoVision for nearly a decade. He succeeds Joanne C. Imperial, M.D., who has stepped down from the Board and will continue to support the Company as an independent clinical consultant.

Dr Shields has maintained a private gastroenterology consulting practice in Palo Alto, California since 1986, providing comprehensive care to patients with gastrointestinal and liver disorders. He previously served as Assistant Professor of Medicine in the Division of Gastroenterology at Stanford University School of Medicine and Director of Endoscopy at Stanford Hospital. A recognized leader in gastrointestinal innovation, Dr Shields established one of the earliest gastroenterology endoscopy programs associated with Stanford University and has been an early adopter and clinical investigator in capsule endoscopy technology. He currently serves as a gastroenterology consultant and clinician at both San Mateo County Medical Center and the Palo Alto Veterans Affairs Health Care System, where he continues to teach medical residents and gastroenterology fellows. Dr Shields has nearly two decades of experience utilizing capsule endoscopy in the diagnosis and management of small bowel disorders and gastrointestinal bleeding.

“We are delighted to welcome David to our Board of Directors,” said Johnny Wang, President and Chief Executive Officer of CapsoVision. “Since 2017, he has been a trusted clinical advisor to CapsoVision. As we approach several important milestones, including the anticipated commercial launch of our AI-assisted reading feature for CapsoCam Plus®, the continued advancement of our second-generation CapsoCam Colon™ program, and the expected expansion of our broader capsule platform, we believe the Company is entering an exciting new phase of growth. David’s deep clinical expertise, extensive experience in capsule endoscopy, and longstanding knowledge of gastrointestinal clinical practice make him an invaluable addition to our Board.”

“I am honored to join CapsoVision’s Board at such an exciting time for the Company,” said Dr Shields. “Having worked alongside the team for many years, I’ve seen firsthand the innovation behind its technology and its commitment to improving patient care. I believe CapsoVision is well positioned to advance the next generation of AI-enabled capsule endoscopy, and I look forward to helping guide the Company’s continued growth and clinical impact.”

Wang continued, “On behalf of the Board and the entire CapsoVision team, I also want to thank Dr Joanne Imperial for her many contributions as a director. We are pleased that she will continue to support CapsoVision as a close clinical advisor, providing ongoing guidance for our pancreatic cancer clinical program and our planned 2027 esophageal varices study, which will evaluate our next-generation capsule platform incorporating Canon’s advanced imaging technology. We look forward to continuing to benefit from Joanne’s clinical expertise as we advance these important programs.”
MB Bureau